Can I stop taking ritexitinib? Long-term drug dependence issues

Ritlecitinib is a JAK3/TEC family kinase inhibitor, mainly used to treat autoimmune diseases such as alopecia areata. Its mechanism of action is to regulate abnormally active immune responses by selectively inhibiting key kinases related to immune signaling pathways to achieve therapeutic purposes. Because it targets chronic and relapsing immune system disorders, many patients are worried: Once they start taking ritexitinib, will they have to rely on it for a long time and cannot stop taking it? Current research and clinical practice suggest that ritexitinib does require long-term management and use, but this does not mean that there is a risk of drug dependence. Dependence is common with central nervous system drugs, but ritexitinib is not addictive. However, it should be noted that sudden discontinuation of medication may cause the disease to relapse, especially in diseases that are prone to relapse such as alopecia areata.

According to the current clinical experience overseas and domestically, the efficacy of ritexitinib usually begins to appear after continuous medication3-6 months, and some patients need to maintain medication for a longer period of time to consolidate the efficacy. Once symptoms improve significantly, some doctors will try to gradually reduce the dose or discontinue the medication based on the patient's individual condition, but this must be done cautiously under the guidance of a specialist. The discontinuation strategy of such drugs usually relies on comprehensive judgments such as the risk of recurrence, the patient's immune status, and the stability of clinical indicators.

Therefore, although ritexitinib is not addictive, it has a strong control effect on chronic diseases and requires continuous medication to maintain the efficacy. The key to the problem of drug withdrawal is not "whether it can be stopped", but "how to stop it scientifically". At present, no clear guidelines for discontinuation of medication have been established at home and abroad, but it is recommended that every decision to reduce or discontinue medication should be based on individualized assessment rather than discretionary decision-making.

Reference materials:https://www.litfulo.com/